Co-Authors
This is a "connection" page, showing publications co-authored by Kamal Dua and Harish Dureja.
Connection Strength
1.279
-
Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics. Drug Dev Res. 2021 11; 82(7):880-882.
Score: 0.240
-
Role of chitosan based nanomedicines in the treatment of chronic respiratory diseases. Int J Biol Macromol. 2021 Aug 31; 185:20-30.
Score: 0.237
-
Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations. J Mol Neurosci. 2021 Nov; 71(11):2192-2209.
Score: 0.231
-
Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis. Med Hypotheses. 2020 Nov; 144:110254.
Score: 0.226
-
Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19. Heliyon. 2021 Jul; 7(7):e07635.
Score: 0.060
-
Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies. AAPS PharmSciTech. 2021 Jun 08; 22(5):173.
Score: 0.059
-
Calcium sensing receptor hyperactivation through viral envelop protein E of SARS CoV2: A novel target for cardio-renal damage in COVID-19 infection. Drug Dev Res. 2021 09; 82(6):784-788.
Score: 0.058
-
An overview of vaccine development for COVID-19. Ther Deliv. 2021 03; 12(3):235-244.
Score: 0.058
-
Probing 3CL protease: Rationally designed chemical moieties for COVID-19. Drug Dev Res. 2020 Jul 30.
Score: 0.056
-
COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. Pharm Nanotechnol. 2020; 8(4):323-353.
Score: 0.054